Today, the product adenosine injection was approved for marketing by the National Medical Products Administration (NMPA) for myocardial perfusion imaging and echocardiographic drug loading tests to aid in the diagnosis of coronary artery disease. This is the only loading drug with both indications in China, providing a new option for non-invasive examination of myocardial ischemia in patients with coronary artery disease.

Coronary heart disease is one of the top five deadly diseases in China. Early detection and diagnosis are the key to controlling the development of coronary heart disease, preventing myocardial infarction and reducing mortality. Loaded non-invasive imaging function test is the main means of diagnosing coronary heart disease and is the “gold standard” for diagnosing myocardial ischemia.

Loaded non-invasive imaging function test can increase myocardial work done by exercise load or drug load, thus increasing myocardial oxygen consumption for the purpose of inducing myocardial ischemia; or induce redistribution of coronary blood flow by dilating coronary arteries, thus achieving the diagnosis of myocardial ischemia.

However, some patients are not suitable for exercise load or are unable to achieve the cardiac load required for optimal imaging through exercise. Adenosine injection offers a new option for these patients—diagnosing myocardial ischemia through drug-loaded myocardial perfusion imaging, addressing their urgent clinical needs.

The approval of adenosine injection is deemed to have passed the consistency evaluation, and it is a Class B drug under national medical insurance. The efficacy, sensitivity and specificity of adenosine injection are high and it has been recommended by the consensus of domestic and foreign guidelines. In addition, adenosine injection, whose metabolic route does not go through the liver and kidney, and adverse reactions are transient, has a good safety profile. Adenosine injection is of great value for the diagnosis, risk stratification, treatment decision and prognosis assessment of coronary heart disease.